Independent data monitoring committee advises aducanumab unlikely to meet primary endpoints, leading to decision to discontinue the trials Cambridge, March…
Data Includes Additional Analyses of Long-Term Extension Phase 1b Study With Titration Cohort at 36 Months and Fixed-Dose Cohorts at…
Thirteen presentations to be given including on Phase II study results of BAN2401 and elenbecestat Tokyo, July 23, 2018: Eisai…